UroGen Pharma Investor Relations Material
Latest events
AGM 2025
UroGen Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from UroGen Pharma Ltd
Access all reports
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers. The company utilizes its proprietary RTGel technology, a reverse-thermal hydrogel that enhances the therapeutic profiles of existing drugs by providing longer exposure to the urinary tract tissue, making local therapy more effective. The company is headquartered in Princeton, NJ, with operations in Israel, and its shares are listed on the Nasdaq.
Key slides for UroGen Pharma Ltd
Study Update
UroGen Pharma Ltd
Study Update
UroGen Pharma Ltd
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
URGN
Country
🇺🇸 United States